Lake Street Maintains Buy on AVITA Medical, Raises Price Target to $20

Benzinga · 2d ago
Lake Street analyst Frank Takkinen maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $20.